One thing patients must know when taking the drug: the efficacy and role of moboxetinib

Mobocertinib is a novel tyrosine kinase inhibitor (TKI) recently approved as the first small molecule treatment for EGFR ex20ins-positive non-small cell lung cancer. Compared with osimertinib (a TKI used to treat EGFR T790M-positive non-small cell lung cancer) , mobosertinib differs only in the presence of an additional C5-carboxylic acid isopropyl ester group on the middle pyrimidine core.

A non-randomized, open-label, multi-short-term Phase 1/2 study found that mobosetinib had an overall response rate of 25-28%, a disease control rate of 76-78%, and a median progression-free survival of 7.3 months. Within the cohort, the median duration of response was not estimable, and overall survival had not been reached at the study's reported data cutoff. The median duration of response was 17.5 months and the median overall survival was 24.0 months. These findings are consistent with the durable substantial tumoricidal effect and even higher tumor suppressive effect of mobosertinib.

Mobosetinib The original drug is currently on the market in China and has not yet been included in the medical insurance. SpecificationThe price of 40mg*112 pills per box is about 40,000 yuan, which is very expensive.The Hong Kong version of the original drug Specifications40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. The drug ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory40mg*120 pills per boxThe pricemay be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.